Renaxen 5 mg (Axitinib INN)

Targeted VEGFR Inhibitor for Advanced Renal Cell Carcinoma

🔹 Short Description

Renaxen® 5 mg contains Axitinib INN, a potent oral tyrosine kinase inhibitor (TKI) that selectively blocks vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). It is indicated for the treatment of advanced renal cell carcinoma (RCC) and helps inhibit tumor angiogenesis, thereby slowing tumor growth and disease progression.

💊 Pharmacology

Axitinib is a highly selective inhibitor of VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3). By blocking these receptors, Renaxen® effectively inhibits angiogenesis—the process by which tumors develop new blood vessels to sustain their growth.

Renaxen® works by:

• Inhibiting VEGF-mediated angiogenesis
• Restricting blood supply to tumors
• Slowing tumor growth and metastasis
• Improving progression-free survival in patients with advanced renal cell carcinoma

Its targeted mechanism offers effective treatment while minimizing damage to healthy tissues.

📌 Indications

Renaxen® 5 mg is indicated for:

• Treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
• First-line treatment of advanced RCC in combination with approved immunotherapy, where clinically appropriate.
• Other indications as recommended by current oncology treatment guidelines.

Treatment should always be initiated and supervised by an experienced oncologist.

💉 Dosage & Administration

• Recommended starting dose: 5 mg orally twice daily.
• Tablets may be taken with or without food.
• Swallow tablets whole with water.
• Dose adjustments may be required depending on individual tolerability and adverse reactions.
• Continue treatment until disease progression or unacceptable toxicity occurs.

Patients should follow their physician's instructions carefully.

⚠️ Precautions & Warnings

Careful monitoring is recommended during treatment for:

• Hypertension (blood pressure should be monitored regularly)
• Liver function abnormalities
• Proteinuria
• Hemorrhagic events
• Arterial and venous thromboembolic events
• Gastrointestinal perforation or fistula
• Impaired wound healing (temporary interruption may be necessary before surgery)
• Thyroid dysfunction

Regular clinical evaluation is recommended throughout therapy.

❌ Contraindications

• Known hypersensitivity to Axitinib or any component of the formulation.

🤰 Pregnancy & Lactation

• Renaxen® may cause fetal harm if administered during pregnancy.
• Women of childbearing potential should use effective contraception during treatment and for an appropriate period after the final dose.
• Breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.

⚕️ Side Effects

Common Side Effects

• Hypertension
• Diarrhea
• Fatigue
• Decreased appetite
• Nausea
• Weight loss
• Dysphonia (hoarseness)
• Hand-foot syndrome
• Hypothyroidism

Serious Side Effects

• Severe hypertension
• Hemorrhage
• Blood clots
• Heart failure
• Liver toxicity
• Gastrointestinal perforation
• Posterior reversible encephalopathy syndrome (PRES)

Patients should seek immediate medical attention if serious adverse reactions occur.

💊 Drug Interactions

• Strong CYP3A4 inhibitors may increase Axitinib plasma concentrations.
• Strong CYP3A4 inducers may reduce therapeutic effectiveness.
• Caution should be exercised when used with anticoagulants or antihypertensive medications.

Patients should inform their physician about all prescription medicines, over-the-counter drugs, and herbal supplements.

🧊 Storage Conditions

• Store below 30°C.
• Protect from moisture and direct sunlight.
• Keep in the original package until use.
• Keep out of the reach of children.

🔖 Therapeutic Class

Antineoplastic Agent
Targeted Therapy
Tyrosine Kinase Inhibitor (VEGFR Inhibitor)

⭐ Key Benefits

• Targeted inhibition of VEGF receptors
• Reduces tumor blood vessel formation
• Helps slow progression of advanced kidney cancer
• Convenient oral twice-daily dosing
• Proven efficacy in advanced renal cell carcinoma
• Suitable for use as monotherapy or in selected combination regimens